The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Another striking feature of these drugs is their ability to reduce risks and mortality from diseases not directly tied to diabetes or obesity (their primary indications). The effects are measurable but modest—around 20-30% risk reduction in cardiovascular events, for instance, which might translate to a few extra years under the Gompertz law of mortality.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.